Literature DB >> 24784920

Validation of a histopathologic classification scheme for antineutrophil cytoplasmic antibody-associated glomerulonephritis.

Erik Nohr1, Louis Girard2, Matthew James3, Hallgrimur Benediktsson4.   

Abstract

Antineutrophil cytoplasmic antibody-associated small-vessel vasculitides cause multiple organ system disease including rapidly progressive glomerulonephritis. Recently, Berden et al (J Am Soc Nephrol. 2010;21:1628-1636) proposed a new histopathologic classification scheme separating renal biopsies into 4 classes: focal, crescentic, mixed, and sclerotic. We validated the prognostic implications of this classification scheme in a retrospective cohort study of 67 individuals with antineutrophil cytoplasmic antibody glomerulonephritis who underwent kidney biopsy in Calgary, Alberta, between 2005 and 2010. Their biopsies were rescored according to the classification scheme of Berden et al. Additional tubulointerstitial parameters were also scored. Clinical information including demographics and creatinine values at presentation and 1-year follow-up was retrieved. The mean age was 60 years. Forty-one percent were female. Biopsies were classified as follows: 35% crescentic, 32% mixed, 21% focal, and 11% sclerotic. Ten patients (14%) died within 1 year. Among surviving patients, the overall mean (95% confidence interval) change in estimated glomerular filtration rate (eGFR) at 1 year was 11 (7-15) mL/min per 1.73 m(2), and this change significantly differed (P = .02) between the classes: 19 (11-27) mL/min per 1.73 m(2) with crescentic histology, 11 (1-21) mL/min per 1.73 m(2) with focal, 8 (3-13) mL/min per 1.73 m(2) with mixed, and -4 (-7 to -1) mL/min per 1.73 m(2) with sclerotic. Tubulointerstitial pathology parameters did not predict outcomes. Patients with crescentic class biopsies showed significantly more improvement in eGFR at 1 year compared with the mixed (P = .04) and sclerotic (P = .005) classes. The focal class was associated with the highest eGFR values at presentation and 1 year. These findings validate the prognostic utility of the Berden classification scheme and suggest that it may be generalizable.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ANCA; Classification; Glomerulonephritis; Histology; Pathology; Prognosis; Vasculitis

Mesh:

Substances:

Year:  2014        PMID: 24784920     DOI: 10.1016/j.humpath.2014.02.017

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  16 in total

1.  Risk Factors for Renal Survival in Chinese Patients with Myeloperoxidase-ANCA-Associated GN.

Authors:  Yinghua Chen; Hao Bao; Zhengzhao Liu; Xia Liu; Erzhi Gao; Caihong Zeng; Haitao Zhang; Zhihong Liu; Weixin Hu
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-01       Impact factor: 8.237

Review 2.  Histopathologic classification of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis: achievements, limitations, and perspectives.

Authors:  Andrea Hinojosa-Azaola; Ariadna Jiménez-González
Journal:  Clin Rheumatol       Date:  2017-06-14       Impact factor: 2.980

3.  Prognostic Value of Histologic Classification of ANCA-Associated Glomerulonephritis.

Authors:  Rune Bjørneklett; Sanjeevan Sriskandarajah; Leif Bostad
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-18       Impact factor: 8.237

4.  Modified histopathological classification with age-related glomerulosclerosis for predicting kidney survival in ANCA-associated glomerulonephritis.

Authors:  Mehmet Fethullah Aydın; Abdülmecit Yıldız; Ayşegül Oruç; Berna Aytaç Vuruşkan; Suat Akgür; Yavuz Ayar; Mustafa Güllülü; Kamil Dilek; Mahmut Yavuz; Hatice Ortaç; Alparslan Ersoy
Journal:  Int Urol Nephrol       Date:  2022-09-25       Impact factor: 2.266

5.  Long-term renal outcome in pediatric glomerulonephritis associated with crescent formation.

Authors:  Pornpimol Rianthavorn; Manunya Chacranon
Journal:  Clin Exp Nephrol       Date:  2017-11-03       Impact factor: 2.801

Review 6.  An evaluation of the 2010 histopathological classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a Bayesian network meta-analysis.

Authors:  Shanshan Huang; Qing Shen; Ruoqing Yang; Heng Lai; Jing Zhang
Journal:  Int Urol Nephrol       Date:  2018-07-25       Impact factor: 2.370

Review 7.  Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis.

Authors:  Emma E van Daalen; Maria A C Wester Trejo; Arda Göçeroğlu; Franco Ferrario; Kensuke Joh; Laure-Hélène Noël; Yayoi Ogawa; Suzanne Wilhelmus; Miriam J Ball; Eva Honsova; Zdenka Hruskova; Renate Kain; Tomoyoshi Kimura; Marek Kollar; Andreas Kronbichler; Kristine Lindhard; Xavier Puéchal; Steven Salvatore; Wladimir Szpirt; Hideki Takizawa; Vladimir Tesar; Annelies E Berden; Olaf M Dekkers; E Christiaan Hagen; Jan Oosting; Chinar Rahmattulla; Ron Wolterbeek; Willem Jan Bos; Jan A Bruijn; Ingeborg M Bajema
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-28       Impact factor: 8.237

8.  ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study.

Authors:  Iuliana Andreiana; Simona Stancu; Andreea Avram; Ludmila Taran; Gabriel Mircescu
Journal:  BMC Nephrol       Date:  2015-06-30       Impact factor: 2.388

Review 9.  Pauci-Immune Crescentic Glomerulonephritis: An ANCA-Associated Vasculitis.

Authors:  Rafeel Syed; Amina Rehman; Gautam Valecha; Suzanne El-Sayegh
Journal:  Biomed Res Int       Date:  2015-11-25       Impact factor: 3.411

10.  Reappraisal of Renal Arteritis in ANCA-associated Vasculitis: Clinical Characteristics, Pathology, and Outcome.

Authors:  Idris Boudhabhay; Florence Delestre; Guillaume Coutance; Viviane Gnemmi; Thomas Quemeneur; Cyrille Vandenbussche; Helene Lazareth; Guillaume Canaud; Leila Tricot; Clément Gosset; Aurélie Hummel; Benjamin Terrier; Marion Rabant; Emma E van Daalen; Maria A C Wester Trejo; Ingeborg M Bajema; Alexandre Karras; Jean-Paul Duong Van Huyen
Journal:  J Am Soc Nephrol       Date:  2021-06-21       Impact factor: 14.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.